Which company developed Relugolix?

Relugolix is developed and produced by Takeda Pharmaceuticals. Relugolix is an oral small-molecule gonadotropin-releasing hormone (GnRH) antagonist that can effectively block androgen production and is used to treat advanced prostate cancer. Regaglic therapy may be associated with lower rates of serum enzyme elevations during treatment but has not been associated with clinically apparent acute liver injury.

Regaglicis a small molecule, non-peptide gonadotropin-releasing hormone (GnRH) antagonist that blocks GnRH’s response to The pituitary gland produces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) stimulation, thereby reducing the synthesis of testosterone in the male testicles and female ovaries. Repagliflozin has been found to relieve advanced prostate cancer with efficacy comparable to that of parenterally administered GnRH peptide analogs such as leuprolide and degarelix. Because repagliflozin is an GnRH antagonist, it does not cause the initial increase in testosterone synthesis seen with GnRH agonists and generally has a faster onset of action. Repagliflox was approved for use in the United States in 2020. Its current indication is limited to the treatment of advanced prostate cancer. GnRHAnalogs are also used for precocious puberty, infertility, and gender confirmation therapy. Repaglifloxis sold as 120 mg tablets under the brand name Orgovyk. The usual initial loading dose is 360 mg (3 tablets), followed by 120 mg daily. Common side effects include symptoms of hypogonadism such as hot flashes, decreased libido, thinning or loss of hair, erectile dysfunction, nausea, diarrhea, weight gain, and fluid retention. Rare but potentially serious adverse reactions include QT/QTc prolongation, hypersensitivity reactions [including angioedema], and embryonotoxicity. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.